Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

The status and prognostic value of the disagreement between physician and patient assessments of symptomatic adverse events (AEs) remain unclear for patients with metastatic colorectal cancer treated with first‐line cetuximab plus chemotherapy. Paired data on patient‐reported outcomes using the EORT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooki, Akira, Morita, Satoshi, Tsuji, Akihito, Iwamoto, Shigeyoshi, Hara, Hiroki, Tanioka, Hiroaki, Satake, Hironaga, Kataoka, Masato, Kotaka, Masahito, Kagawa, Yoshinori, Nakamura, Masato, Shingai, Tatsushi, Ishikawa, Masashi, Miyake, Yasuhiro, Suto, Takeshi, Hashiguchi, Yojiro, Yabuno, Taichi, Ando, Masahiko, Sakamoto, Junichi, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774728/
https://www.ncbi.nlm.nih.gov/pubmed/33222406
http://dx.doi.org/10.1002/cam4.3564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774728/
https://www.ncbi.nlm.nih.gov/pubmed/33222406
http://dx.doi.org/10.1002/cam4.3564

Ejemplares similares